Treatment of mice bearing Thy1.1-antibody-induced MPGN with Erlotinib, a selective EGFR inhibitor, significantly attenuated the glomerular inflammatory response, mesangial cell proliferation, matrix accumulation and further, preserved renal function (Rintala et al., 2016). This evidence concerns the gene EGFR and primary membranoproliferative glomerulonephritis.